Boehringer Ingelheim’s BIBW 2992 for the treatment of late stage non small cell lung cancer (NSCLC)

14 February 2008 – Boehringer Ingelheim’s investigational cancer treatment BIBW 2992 has recently received a Fast Track Designation status by the FDA. Under this designation, Boehringer Ingelheim will conduct a pivotal trial programme studying BIBW 2992 in a non-small cell lung cancer (NSCLC) patient group where prior treatment with reversible EGFR inhibitors has failed.
The FDA`s Fast Track Programme will facilitate the development programme and expedite the review of new treatments that demonstrate the potential to address an unmet medical need in serious or life-threatening diseases... Boehringer Ingelheim’s Press Release -